Summary
3.46 -0.14(-3.89%)07/08/2024
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.89 | -10.36 | -12.63 | -26.38 | -13.07 | -24.29 | 0.00 | -86.79 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.46 | |
| Open | 3.65 | |
| High | 3.70 | |
| Low | 3.45 | |
| Volume | 21,127 | |
| Change | -0.14 | |
| Change % | -3.89 | |
| Avg Volume (20 Days) | 40,158 | |
| Volume/Avg Volume (20 Days) Ratio | 0.53 | |
| 52 Week Range | 1.66 - 5.83 | |
| Price vs 52 Week High | -40.65% | |
| Price vs 52 Week Low | 108.43% | |
| Range | -5.21 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 198 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 41.75 | |
| Book Value | 6.7150 | |
| Earnings Per Share | -2.1760 | |
| EPS Estimate Current Quarter | -0.6300 | |
| EPS Estimate Next Quarter | -0.6600 | |
| EPS Estimate Current Year | -2.4000 | |
| EPS Estimate Next Year | -3.3600 | |
| Diluted EPS (TTM) | -2.1760 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.2193 | |
| Return on equity (TTM) | -0.3636 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.0935 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 35,813,300 | |
| Shares Float | 11,719,482 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.15 | |
| Institutions (%) | 88.01 | |
06/03 07:01 EST - globenewswire.com
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
05/09 07:01 EST - globenewswire.com
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.
05/07 07:01 EST - globenewswire.com
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024
04/09 16:35 EST - globenewswire.com
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
03/05 16:45 EST - globenewswire.com
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company's highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company's highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.
02/29 16:05 EST - globenewswire.com
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.
02/15 16:05 EST - globenewswire.com
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024
01/25 07:41 EST - zacks.com
New Strong Buy Stocks for January 25th
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
New Strong Buy Stocks for January 25th
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
12/11 09:34 EST - globenewswire.com
Prelude Therapeutics Announces $25 Million Private Placement
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working capital and general corporate purposes.
Prelude Therapeutics Announces $25 Million Private Placement
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working capital and general corporate purposes.
11/01 16:10 EST - globenewswire.com
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program being a SMARCA degrader-antibody conjugate Cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program being a SMARCA degrader-antibody conjugate Cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.
10/14 12:30 EST - globenewswire.com
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude's CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789.
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude's CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789.
10/04 13:31 EST - zacks.com
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
08/29 08:30 EST - globenewswire.com
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:
08/03 08:00 EST - globenewswire.com
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude's pipeline through critical milestones WILMINGTON, Del., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude's pipeline through critical milestones WILMINGTON, Del., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
04/27 08:30 EST - globenewswire.com
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences.
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences.
04/11 08:30 EST - globenewswire.com
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
03/18 18:48 EST - investorplace.com
The 7 Worst Stocks to Buy Now
Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a flood of messages from people defending the honor of corporations who could care less about them.
The 7 Worst Stocks to Buy Now
Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a flood of messages from people defending the honor of corporations who could care less about them.
03/16 13:46 EST - zacks.com
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
02/09 09:05 EST - globenewswire.com
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.
08/10 10:32 EST - zacks.com
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.